Escape from Human Immunodeficiency Virus Type 1 (HIV-1) Entry Inhibitors

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2013 Jan 25

PMID 23342377

Citations 23

Authors

Christopher J De Feo

Carol D Weiss

Affiliations

Soon will be listed here.

Abstract

The human immunodeficiency virus (HIV) enters cells through a series of molecular interactions between the HIV envelope protein and cellular receptors, thus providing many opportunities to block infection. Entry inhibitors are currently being used in the clinic, and many more are under development. Unfortunately, as is the case for other classes of antiretroviral drugs that target later steps in the viral life cycle, HIV can become resistant to entry inhibitors. In contrast to inhibitors that block viral enzymes in intracellular compartments, entry inhibitors interfere with the function of the highly variable envelope glycoprotein as it continuously adapts to changing immune pressure and available target cells in the extracellular environment. Consequently, pathways and mechanisms of resistance for entry inhibitors are varied and often involve mutations across the envelope gene. This review provides a broad overview of entry inhibitor resistance mechanisms that inform our understanding of HIV entry and the design of new inhibitors and vaccines.

Citing Articles

A New Chimeric Antibody against the HIV-1 Fusion Inhibitory Peptide MT-C34 with a High Affinity and Fc-Mediated Cellular Cytotoxicity.

Kalinichenko S, Ramadan L, Kruglova N, Balagurov K, Lukashina M, Mazurov D Biology (Basel). 2024; 13(9).

PMID: 39336102 PMC: 11428423. DOI: 10.3390/biology13090675.

Human Papillomavirus Carcinogenicity and the Need of New Perspectives: Thoughts from a Retrospective Analysis on Human Papillomavirus Outcomes Conducted at the Hospital University of Bari, Apulia, Italy, between 2011 and 2022.

Del Prete R, Nesta D, Triggiano F, Lorusso M, Garzone S, Vitulano L Diagnostics (Basel). 2024; 14(9).

PMID: 38732382 PMC: 11083870. DOI: 10.3390/diagnostics14090968.

The Phenomenon of Antiretroviral Drug Resistance in the Context of Human Immunodeficiency Virus Treatment: Dynamic and Ever Evolving Subject Matter.

Apetroaei M, Velescu B, Nedea M, Dinu-Pirvu C, Draganescu D, Faca A Biomedicines. 2024; 12(4).

PMID: 38672269 PMC: 11048092. DOI: 10.3390/biomedicines12040915.

Peptide-Based Dual HIV and Coronavirus Entry Inhibitors.

Wang H, Wang C Adv Exp Med Biol. 2022; 1366:87-100.

PMID: 35412136 DOI: 10.1007/978-981-16-8702-0_6.

Engineering T-Cell Resistance to HIV-1 Infection via Knock-In of Peptides from the Heptad Repeat 2 Domain of gp41.

Maslennikova A, Kruglova N, Kalinichenko S, Komkov D, Shepelev M, Golubev D mBio. 2022; 13(1):e0358921.

PMID: 35073736 PMC: 8787484. DOI: 10.1128/mbio.03589-21.

References

Chan D, Chutkowski C, Kim P . Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci U S A. 1998; 95(26):15613-7. PMC: 28092. DOI: 10.1073/pnas.95.26.15613. View

Anastassopoulou C, Ketas T, Klasse P, Moore J . Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc Natl Acad Sci U S A. 2009; 106(13):5318-23. PMC: 2664029. DOI: 10.1073/pnas.0811713106. View

Perez-Alvarez L, Carmona R, Ocampo A, Asorey A, Miralles C, Perez de Castro S . Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1. J Med Virol. 2005; 78(2):141-7. DOI: 10.1002/jmv.20520. View

Yu X, Lu L, Cai L, Tong P, Tan S, Zou P . Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket. J Virol. 2011; 86(1):589-93. PMC: 3255876. DOI: 10.1128/JVI.05066-11. View

Tsibris A, Sagar M, Gulick R, Su Z, Hughes M, Greaves W . In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol. 2008; 82(16):8210-4. PMC: 2519584. DOI: 10.1128/JVI.00444-08. View

Trkola A, Dragic T, Arthos J, Binley J, Olson W, Allaway G . CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature. 1996; 384(6605):184-7. DOI: 10.1038/384184a0. View

Farzan M, Choe H, Vaca L, Martin K, Sun Y, DESJARDINS E . A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J Virol. 1998; 72(2):1160-4. PMC: 124591. DOI: 10.1128/JVI.72.2.1160-1164.1998. View

Rimsky L, Shugars D, Matthews T . Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol. 1998; 72(2):986-93. PMC: 124569. DOI: 10.1128/JVI.72.2.986-993.1998. View

Yoshimura K, Harada S, Shibata J, Hatada M, Yamada Y, Ochiai C . Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. J Virol. 2010; 84(15):7558-68. PMC: 2897603. DOI: 10.1128/JVI.00227-10. View

10.

Tolstrup M, Selzer-Plon J, Laursen A, Bertelsen L, Gerstoft J, Duch M . Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K). AIDS. 2007; 21(4):519-21. DOI: 10.1097/QAD.0b013e3280187558. View

11.

Sen J, Jacobs A, Jiang H, Rong L, Caffrey M . The disulfide loop of gp41 is critical to the furin recognition site of HIV gp160. Protein Sci. 2007; 16(6):1236-41. PMC: 2206660. DOI: 10.1110/ps.072771407. View

12.

Kuritzkes D . HIV-1 entry inhibitors: an overview. Curr Opin HIV AIDS. 2009; 4(2):82-7. PMC: 2753507. DOI: 10.1097/COH.0b013e328322402e. View

13.

Liu Z, Shan M, Li L, Lu L, Meng S, Chen C . In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem. 2010; 286(5):3277-87. PMC: 3030333. DOI: 10.1074/jbc.M110.199323. View

14.

Yao X, Chong H, Zhang C, Waltersperger S, Wang M, Cui S . Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide. J Biol Chem. 2012; 287(9):6788-96. PMC: 3307288. DOI: 10.1074/jbc.M111.317883. View

15.

Zaitseva M, Peden K, Golding H . HIV coreceptors: role of structure, posttranslational modifications, and internalization in viral-cell fusion and as targets for entry inhibitors. Biochim Biophys Acta. 2003; 1614(1):51-61. DOI: 10.1016/s0005-2736(03)00162-7. View

16.

Gonzalez E, Ballana E, Clotet B, Este J . Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP). AIDS. 2011; 25(13):1557-83. DOI: 10.1097/QAD.0b013e328348a733. View

17.

Garcia-Perez J, Rueda P, Staropoli I, Kellenberger E, Alcami J, Arenzana-Seisdedos F . New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection. J Biol Chem. 2010; 286(7):4978-90. PMC: 3037610. DOI: 10.1074/jbc.M110.168955. View

18.

Ray N, Blackburn L, Doms R . HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide. J Virol. 2009; 83(7):2989-95. PMC: 2655552. DOI: 10.1128/JVI.02496-08. View

19.

Daar E, Li X, Moudgil T, Ho D . High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A. 1990; 87(17):6574-8. PMC: 54579. DOI: 10.1073/pnas.87.17.6574. View

20.

Seibert C, Ying W, Gavrilov S, Tsamis F, Kuhmann S, Palani A . Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology. 2006; 349(1):41-54. DOI: 10.1016/j.virol.2006.01.018. View